India's No.1 PU & Degree With Integrated IAS & IPS(UPSC/PSC) Training College.
India Approves First Dengue Vaccine For Wider Public Protection Why in the News ? The Drug Controller General of India (DCGI) has granted market authorisation to QDENGA (TAK-003), making it the first dengue vaccine approved in India. The vaccine is indicated for individuals aged 4–60 years and offers protection against all four dengue virus serotypes. …
Read MoreUnited States Reports Major Cyclosporiasis Foodborne Disease Outbreak Why in the News ? The United States has reported a major outbreak of cyclosporiasis, with over 1,645 confirmed cases across 34 States. The outbreak has renewed global attention on foodborne diseases, food safety practices, surveillance of parasitic infections, and the importance of diplomatic engagement in international …
Read MoreCAR-T CELL THERAPY BREAKTHROUGH IN SOLID TUMOURS Why in the News? Scientists have developed a highly sensitive receptor (HIT receptor) that enables CAR-T cells to detect low-level tumour proteins. The breakthrough could make CAR-T therapy effective against solid cancers like kidney and ovarian cancer, overcoming a long-standing limitation. Key scientific advancement Concept innovation: Uses an …
Read MoreIndia Achieves 21% Decline in Tuberculosis Cases Why in the News ? According to the World Health Organization’s Global TB Report 2025, India recorded a 21% decline in tuberculosis (TB) cases over the last decade — nearly double the global average reduction — showcasing the success of national TB elimination initiatives and improved healthcare coverage. …
Read MoreWhy in the News ? Scientists from Tata Memorial Centre have developed patient-derived organoid and xenograft models to study Signet Ring Cell Carcinoma (SRCC), a rare and aggressive colorectal cancer. This breakthrough could enable targeted therapies and improve treatment outcomes for SRCC patients. New Breakthrough in Rare Colorectal Cancer Research: Scientists have devised advanced methods …
Read MoreWhy in the news? AstraZeneca, known for its COVID-19 vaccine Covishield, withdraws globally due to rare side-effects and surplus availability of updated vaccines. source:reuters Key Points:AstraZeneca Withdraws COVID-19 Vaccine: AstraZeneca, in collaboration with Oxford University, has commenced the global withdrawal of its COVID-19 vaccine. Marketed as ‘Covishield’ in India through a partnership with the Serum …
Read More
